Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma 54Lymphoma 40Lymphoma, Large B-Cell, Diffuse 28Lymphoma, Non-Hodgkin 21Hodgkin Disease 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Osteosarcoma 17Testicular Neoplasms 15Burkitt Lymphoma 15Leukemia 14Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Follicular 13Ovarian Neoplasms 12Lymphoma, Mantle-Cell 12Neuroectodermal Tumors, Primitive, Peripheral 11Testicular Germ Cell Tumor 10Liposarcoma 10Histiocytoma, Malignant Fibrous 10Hemangiosarcoma 10Fibrosarcoma 10Sarcoma, Synovial 9Rhabdomyosarcoma 9Neurofibrosarcoma 9Lymphoma, Large-Cell, Anaplastic 9Leiomyosarcoma 9Teratoma 8Recurrence 8Neuroblastoma 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × Ifosfamide × Clear all
NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡